Assessment of liver disease severity is often overlooked in the management of patients with HBV infection, but it can tip the scales when weighing the decision to treat or monitor.
Rapid expansion of the use of new immunosuppressive agents and failure to screen patients for HBV prior to therapy initiation can lead to HBV reactivation. Here’s my approach to preventing reactivation.
This concise MedicalMinute presentation reviews the APASL guidelines on treatment indications for patients with HBV infection, including a brief discussion of methods to assess fibrosis.
Listen to expert insights on the limitations of the current APASL recommendations for screening and surveilling patients with chronic hepatitis B for hepatocellular carcinoma.
In episode 1 of this ongoing series, listen to a conversation between Grace LH Wong, MD, and her patient, Ms. Chan, on the shared decision for Ms. Chan to start treatment for hepatitis B infection during her pregnancy.
Review APASL guideline recommendations informing HBV treatment candidacy, including fibrosis assessments and ongoing monitoring.